SLAMF7 and AL amyloidosis: FT538 is currently being tested in an open-label, multi-dose phase 1 clinical trial as a monotherapy for the treatment of AML and in combination with a monoclonal antibody against CD38 (daratumumab) or CD319/ SLAMF7 (elotuzumab) for the treatment of multiple myeloma (clinicaltrials.gov: NCT04614636) (Janakiram et al. 2020).